Diastolic Heart Failure
61
5
5
33
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
19.7%
12 terminated out of 61 trials
73.3%
-13.2% vs benchmark
13%
8 trials in Phase 3/4
24%
8 of 33 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 33 completed trials
Clinical Trials (61)
Assessment of CCM in HF With Higher Ejection Fraction
Purinergic Signaling and the Postmenopausal Heart
Parasympathetic Augmentation Via Respiratory Training for Patients With Systolic Heart Failure
ST2 for the Management of Heart Failure - STADE-HF
Left Ventricular Reverse Remodeling Evaluation After Surgical Correction of Aortic Regurgitation
Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES
Investigating Multimodally Endothelial Dysfunction in Ocular and Systemic Disease
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Essential Hypotension and Allostasis Registry
Mathematical Modeling to Determine Basic Muscle Properties in the Failing Heart
2 New Measurements Used to Describe the Filling Phase of the Left Ventricle (LV).
Cardiac Resynchronisation Therapy Versus Rate-responsive Pacing in Heart Failure With Preserved Ejection Fraction
Validation of New Non-Invasive Parameters of Diastolic Suction in the Left Ventricle
Effects of Postural Balance Exercises in Patients With Heart Failure
A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure
Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure
Personalized Pacing: A New Paradigm for Patients With Diastolic Dysfunction or Heart Failure With Preserved Ejection Fraction
Diastolic dYsfunctioN AssessMent in critICally Ill Patients
Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction
Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF